These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 32264757)

  • 1. The importance of developing hyperkalaemia in heart failure during long-term follow-up.
    Martens P; Kooij J; Maessen L; Dauw J; Dupont M; Mullens W
    Acta Cardiol; 2021 Aug; 76(6):589-597. PubMed ID: 32264757
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Patiromer for the management of hyperkalaemia in patients receiving renin-angiotensin-aldosterone system inhibitors for heart failure: design and rationale of the DIAMOND trial.
    Butler J; Anker SD; Siddiqi TJ; Coats AJS; Dorigotti F; Filippatos G; Friede T; Göhring UM; Kosiborod MN; Lund LH; Metra M; Moreno Quinn C; Piña IL; Pinto FJ; Rossignol P; Szecsödy P; Van Der Meer P; Weir M; Pitt B
    Eur J Heart Fail; 2022 Jan; 24(1):230-238. PubMed ID: 34800079
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Experience of a Bespoke Hyperkalaemia Clinic to Facilitate Prescribing of Renin-Angiotensin-Aldosterone System Inhibitors in Patients with Heart Failure with Reduced Ejection Fraction.
    Ali I; Green D; Kalra P; Kalra PA
    Cardiorenal Med; 2022; 12(5-6):196-204. PubMed ID: 36044877
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Unravelling the interplay between hyperkalaemia, renin-angiotensin-aldosterone inhibitor use and clinical outcomes. Data from 9222 chronic heart failure patients of the ESC-HFA-EORP Heart Failure Long-Term Registry.
    Rossignol P; Lainscak M; Crespo-Leiro MG; Laroche C; Piepoli MF; Filippatos G; Rosano GMC; Savarese G; Anker SD; Seferovic PM; Ruschitzka F; Coats AJS; Mebazaa A; McDonagh T; Sahuquillo A; Penco M; Maggioni AP; Lund LH;
    Eur J Heart Fail; 2020 Aug; 22(8):1378-1389. PubMed ID: 32243669
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serum potassium and clinical outcomes in heart failure patients: results of risk calculations in 21 334 patients in the UK.
    Linde C; Qin L; Bakhai A; Furuland H; Evans M; Ayoubkhani D; Palaka E; Bennett H; McEwan P
    ESC Heart Fail; 2019 Apr; 6(2):280-290. PubMed ID: 30629342
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A cost-effectiveness analysis of patiromer in the UK: evaluation of hyperkalaemia treatment and lifelong RAASi maintenance in chronic kidney disease patients with and without heart failure.
    Ward T; Lewis RD; Brown T; Baxter G; de Arellano AR
    BMC Nephrol; 2023 Mar; 24(1):47. PubMed ID: 36890464
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hyperkalaemia as a cause of undertreatment with mineralocorticoid receptor antagonists in heart failure.
    Henrysson J; Thunström E; Chen X; Fu M; Basic C
    ESC Heart Fail; 2023 Feb; 10(1):66-79. PubMed ID: 36161782
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Patiromer for the management of hyperkalemia in heart failure with reduced ejection fraction: the DIAMOND trial.
    Butler J; Anker SD; Lund LH; Coats AJS; Filippatos G; Siddiqi TJ; Friede T; Fabien V; Kosiborod M; Metra M; Piña IL; Pinto F; Rossignol P; van der Meer P; Bahit C; Belohlavek J; Böhm M; Brugts JJ; Cleland JGF; Ezekowitz J; Bayes-Genis A; Gotsman I; Goudev A; Khintibidze I; Lindenfeld J; Mentz RJ; Merkely B; Montes EC; Mullens W; Nicolau JC; Parkhomenko A; Ponikowski P; Seferovic PM; Senni M; Shlyakhto E; Cohen-Solal A; Szecsödy P; Jensen K; Dorigotti F; Weir MR; Pitt B
    Eur Heart J; 2022 Nov; 43(41):4362-4373. PubMed ID: 35900838
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prevalence, clinical impact and costs of hyperkalaemia: Special focus on heart failure.
    Maggioni AP; Dondi L; Andreotti F; Calabria S; Iacoviello M; Gorini M; Gonzini L; Piccinni C; Ronconi G; Martini N
    Eur J Clin Invest; 2021 Aug; 51(8):e13551. PubMed ID: 33786826
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Experience with the potassium binder patiromer in hyperkalaemia management in heart failure patients in real life.
    Esteban-Fernández A; Ortiz Cortés C; López-Fernández S; Recio Mayoral A; Camacho Jurado FJ; Gómez Otero I; Molina M; Almenar Bonet L; López-Vilella R
    ESC Heart Fail; 2022 Oct; 9(5):3071-3078. PubMed ID: 35748119
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Frequency and clinical impact of hyperkalaemia within a large, modern, real-world heart failure population.
    Muhlestein JB; Kammerer J; Bair TL; Knowlton KU; Le VT; Anderson JL; Lappé DL; May HT
    ESC Heart Fail; 2021 Feb; 8(1):691-696. PubMed ID: 33331114
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Real-World Associations of Renin-Angiotensin-Aldosterone System Inhibitor Dose, Hyperkalemia, and Adverse Clinical Outcomes in a Cohort of Patients With New-Onset Chronic Kidney Disease or Heart Failure in the United Kingdom.
    Linde C; Bakhai A; Furuland H; Evans M; McEwan P; Ayoubkhani D; Qin L
    J Am Heart Assoc; 2019 Nov; 8(22):e012655. PubMed ID: 31711387
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term effects of patiromer for hyperkalaemia treatment in patients with mild heart failure and diabetic nephropathy on angiotensin-converting enzymes/angiotensin receptor blockers: results from AMETHYST-DN.
    Pitt B; Bakris GL; Weir MR; Freeman MW; Lainscak M; Mayo MR; Garza D; Zawadzki R; Berman L; Bushinsky DA
    ESC Heart Fail; 2018 Aug; 5(4):592-602. PubMed ID: 29767459
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serum potassium as a predictor of adverse clinical outcomes in patients with chronic kidney disease: new risk equations using the UK clinical practice research datalink.
    Furuland H; McEwan P; Evans M; Linde C; Ayoubkhani D; Bakhai A; Palaka E; Bennett H; Qin L
    BMC Nephrol; 2018 Aug; 19(1):211. PubMed ID: 30134846
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serum potassium level and mineralocorticoid receptor antagonist dose in a large cohort of chronic heart failure patients.
    Clephas PRD; Radhoe SP; Linssen GCM; Langerveld J; Plomp J; Smits JPP; Nagelsmit MJ; Rocca HB; Brugts JJ
    ESC Heart Fail; 2023 Apr; 10(2):1481-1487. PubMed ID: 36738129
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Incidence, predictors and clinical management of hyperkalaemia in new users of mineralocorticoid receptor antagonists.
    Trevisan M; de Deco P; Xu H; Evans M; Lindholm B; Bellocco R; Barany P; Jernberg T; Lund LH; Carrero JJ
    Eur J Heart Fail; 2018 Aug; 20(8):1217-1226. PubMed ID: 29667759
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of an individualized dose titration regimen of patiromer to prevent hyperkalaemia in patients with heart failure and chronic kidney disease.
    Pitt B; Bushinsky DA; Kitzman DW; Ruschitzka F; Metra M; Filippatos G; Rossignol P; Du Mond C; Garza D; Berman L; Lainscak M;
    ESC Heart Fail; 2018 Jun; 5(3):257-266. PubMed ID: 29369537
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reduced Risk of Hyperkalemia During Treatment of Heart Failure With Mineralocorticoid Receptor Antagonists by Use of Sacubitril/Valsartan Compared With Enalapril: A Secondary Analysis of the PARADIGM-HF Trial.
    Desai AS; Vardeny O; Claggett B; McMurray JJ; Packer M; Swedberg K; Rouleau JL; Zile MR; Lefkowitz M; Shi V; Solomon SD
    JAMA Cardiol; 2017 Jan; 2(1):79-85. PubMed ID: 27842179
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of patiromer on reducing serum potassium and preventing recurrent hyperkalaemia in patients with heart failure and chronic kidney disease on RAAS inhibitors.
    Pitt B; Bakris GL; Bushinsky DA; Garza D; Mayo MR; Stasiv Y; Christ-Schmidt H; Berman L; Weir MR
    Eur J Heart Fail; 2015 Oct; 17(10):1057-65. PubMed ID: 26459796
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hyperkalemia and management of renin-angiotensin-aldosterone system inhibitors in chronic heart failure with reduced ejection fraction: A systematic review.
    Fonseca C; Brito D; Branco P; Frazão JM; Silva-Cardoso J; Bettencourt P
    Rev Port Cardiol (Engl Ed); 2020 Sep; 39(9):517-541. PubMed ID: 32868174
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.